{"protocolSection": {"identificationModule": {"nctId": "NCT01555164", "orgStudyIdInfo": {"id": "GS-US-259-0147"}, "secondaryIdInfos": [{"id": "2012-001259-37", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Gilead Sciences", "class": "INDUSTRY"}, "briefTitle": "A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone", "officialTitle": "A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Metformin in Subjects With Type 2 Diabetes Mellitus"}, "statusModule": {"statusVerifiedDate": "2014-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-06"}, "primaryCompletionDateStruct": {"date": "2013-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-03-13", "studyFirstSubmitQcDate": "2012-03-13", "studyFirstPostDateStruct": {"date": "2012-03-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-09-17", "resultsFirstSubmitQcDate": "2014-09-17", "resultsFirstPostDateStruct": {"date": "2014-09-23", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2014-01-17", "dispFirstSubmitQcDate": "2014-01-17", "dispFirstPostDateStruct": {"date": "2014-02-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-09-17", "lastUpdatePostDateStruct": {"date": "2014-09-23", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Gilead Sciences", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determine the effect of ranolazine when added to metformin on glycemic control in adults with type 2 diabetes mellitus (T2DM) who are inadequately controlled despite current treatment with stable metformin therapy in addition to diet and exercise."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 442, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Ranolazine+metformin", "type": "EXPERIMENTAL", "description": "Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening).\n\nTreatment Period: Participants will receive ranolazine 500 mg + metformin 500 mg + placebo to match metformin twice daily on Days 1 through 7, followed by ranolazine 1000 mg + metformin 500 mg + placebo to match metformin twice daily from Day 8 through Week 24.\n\nParticipants are required to maintain their diet and exercise regimen.", "interventionNames": ["Drug: Ranolazine", "Drug: Metformin", "Drug: Placebo to match metformin", "Behavioral: Diet", "Behavioral: Exercise"]}, {"label": "Placebo+metformin", "type": "PLACEBO_COMPARATOR", "description": "Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening).\n\nTreatment Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily through Week 24.\n\nParticipants are required to maintain their diet and exercise regimen.", "interventionNames": ["Drug: Placebo to match ranolazine", "Drug: Metformin", "Behavioral: Diet", "Behavioral: Exercise"]}], "interventions": [{"type": "DRUG", "name": "Ranolazine", "description": "Ranolazine tablet(s) administered orally", "armGroupLabels": ["Ranolazine+metformin"], "otherNames": ["Ranexa\u00ae"]}, {"type": "DRUG", "name": "Placebo to match ranolazine", "description": "Placebo to match ranolazine for the duration of the study", "armGroupLabels": ["Placebo+metformin"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin tablet(s) administered orally once daily", "armGroupLabels": ["Placebo+metformin", "Ranolazine+metformin"]}, {"type": "DRUG", "name": "Placebo to match metformin", "description": "Placebo to match metformin for the duration of the study", "armGroupLabels": ["Ranolazine+metformin"]}, {"type": "BEHAVIORAL", "name": "Diet", "description": "Participants are instructed to continue the diet regimen prescribed by their physician.", "armGroupLabels": ["Placebo+metformin", "Ranolazine+metformin"]}, {"type": "BEHAVIORAL", "name": "Exercise", "description": "Participants are instructed to continue the exercise regimen prescribed by their physician.", "armGroupLabels": ["Placebo+metformin", "Ranolazine+metformin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24", "description": "The average (mean) change from baseline in HbA1c at Week 24 was analyzed.", "timeFrame": "Baseline; Week 24"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Fasting Serum Glucose at Week 24", "description": "The average (mean) change from baseline in fasting serum glucose at Week 24 was analyzed.", "timeFrame": "Baseline; Week 24"}, {"measure": "Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24", "description": "The average (mean) change from baseline in 2-hour postprandial serum glucose at Week 24 was analyzed.\n\nMixed Meal Tolerance Test (MMTT) Full Analysis Set: randomized participants who received at least one dose of study treatment with a baseline and at least one postbaseline measurement of serum glucose at T=120 minutes during the MMTT, administered under fasting conditions, excluding participants with major eligibility protocol violations; analyzed based on the randomized treatment regardless of actual treatment received.", "timeFrame": "Baseline; Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Documented history of T2DM\n* Metformin therapy at a stable total daily dose \u2265 1500 mg and \u2264 2550 mg in addition to diet and exercise for \u2265 8 weeks prior to Screening\n* Body mass index (BMI) 25 to 45 kg/m\\^2, inclusive, at Screening\n* HbA1c within specified ranges at Screening and at the end of the Qualifying Period based on current metformin dose\n* C-peptide \u2265 0.8 ng/mL at Screening\n* Fasting serum glucose (FSG) \u2265 130 mg/dL (7.2 mmol/L) and \u2264 240 mg/dL (13.3 mmol/L) at Screening and at the end of the Qualifying Period\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* History of diabetic ketoacidosis, ketosis-prone diabetes, or hyperosmolar hyperglycemic coma\n* History of severe hypoglycemia\n* Any clinically significant cardiovascular or cerebrovascular event \u2264 3 months prior to Screening\n* History of congestive heart failure\n* Corrected QT interval (QTc) \\> 500 msec by ECG at Screening, a personal or family history of QTc prolongation, congenital long QT syndrome, or individuals who are receiving drugs that prolong the QTc interval, such as Class Ia or Class III antiarrhythmic agents, erythromycin, and certain antipsychotics (eg, ziprasidone)\n* Serum creatinine concentration \u2265 1.5 mg/dL for males or \u2265 1.4 mg/dL for females at Screening\n* Active liver disease and/or significant abnormal liver function defined as aspartate aminotransferase (AST) \\> 3 x upper limit of the normal range (ULN) and/or alanine aminotransferase (ALT) \\> 3 x ULN and/or serum total bilirubin \\> 2.0 mg/dL\n* Use of any non-insulin antihyperglycemic therapy (other than metformin) for more than 14 days (consecutive or not) during the 12 weeks (24 weeks for thiazolidinediones) prior to Screening and/or use of any antihyperglycemic therapy other than metformin, at any dose, at any time during the 4 weeks prior to randomization\n* Treatment with chronic insulin within 24 weeks prior to Screening (except for one temporary period of daily insulin injections no longer than 7 days)\n* Treatment with strong or moderate cytochrome P450 3A (CYP3A) inhibitors or P-glycoprotein (P-gp) inhibitors within 14 days prior to randomization\n* Treatment with CYP3A inducers or P-gp inducers within 14 days prior to randomization\n* Treatment with simvastatin or lovastatin at a dose \\> 20 mg or \\> 40 mg daily, respectively, within 14 days prior to randomization", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Patrick Yue, MD", "affiliation": "Gilead Sciences", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Fundamental Research LLC", "city": "Gulf Shores", "state": "Alabama", "zip": "36542", "country": "United States", "geoPoint": {"lat": 30.24604, "lon": -87.70082}}, {"facility": "KLR Business Group DBA Arkansas Clinical Research", "city": "Little Rock", "state": "Alaska", "zip": "72205", "country": "United States"}, {"facility": "Radiant Research, Inc.", "city": "Chandler", "state": "Arizona", "zip": "85224", "country": "United States", "geoPoint": {"lat": 33.30616, "lon": -111.84125}}, {"facility": "Central Phoenix Medical Clinic", "city": "Phoenix", "state": "Arizona", "zip": "85020", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Clinical Research Advantage", "city": "Tempe", "state": "Arizona", "zip": "85282", "country": "United States", "geoPoint": {"lat": 33.41477, "lon": -111.90931}}, {"facility": "Desert Sun Clinical Research, LLC", "city": "Tucson", "state": "Arizona", "zip": "85710", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "National Research Institute", "city": "Los Angeles", "state": "California", "zip": "90057", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Ritchken and First MD's", "city": "San Diego", "state": "California", "zip": "92117", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Clearview Medical Research, LLC", "city": "Santa Clarita", "state": "California", "zip": "91350", "country": "United States", "geoPoint": {"lat": 34.39166, "lon": -118.54259}}, {"facility": "Metabolic Institute of America", "city": "Tarzana", "state": "California", "zip": "91356", "country": "United States", "geoPoint": {"lat": 34.17334, "lon": -118.55397}}, {"facility": "University Clinical Investigators", "city": "Tustin", "state": "California", "zip": "92780", "country": "United States", "geoPoint": {"lat": 33.74585, "lon": -117.82617}}, {"facility": "Infosphere Clinical Research", "city": "West Hills", "state": "California", "zip": "91307", "country": "United States", "geoPoint": {"lat": 34.19731, "lon": -118.64398}}, {"facility": "Colorado Springs Health Partners", "city": "Colorado Springs", "state": "Colorado", "zip": "80906", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Boca Raton Clinical Research Associates, Inc.", "city": "Boca Raton", "state": "Florida", "zip": "33432", "country": "United States", "geoPoint": {"lat": 26.3669, "lon": -80.13033}}, {"facility": "MD Clinical Institute", "city": "Hallandale Beach", "state": "Florida", "zip": "33009", "country": "United States", "geoPoint": {"lat": 25.9812, "lon": -80.14838}}, {"facility": "A G A Clinical Trials", "city": "Hialeah", "state": "Florida", "zip": "33012", "country": "United States", "geoPoint": {"lat": 25.8576, "lon": -80.27811}}, {"facility": "Baptist Diabetes Associates", "city": "Miami", "state": "Florida", "zip": "33156", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Florida Institute for Clinical Research LLC", "city": "Orlando", "state": "Florida", "zip": "32822", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Medical Research Group of Central Florida", "city": "Sanford", "state": "Florida", "zip": "32771", "country": "United States", "geoPoint": {"lat": 28.80041, "lon": -81.27319}}, {"facility": "Synergy Therapeutic Partners", "city": "Atlanta", "state": "Georgia", "zip": "30312", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Perimeter Institute for Clinical Research", "city": "Atlanta", "state": "Georgia", "zip": "30338", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Columbus Research Foundation", "city": "Columbus", "state": "Georgia", "zip": "31904", "country": "United States", "geoPoint": {"lat": 32.46098, "lon": -84.98771}}, {"facility": "Advanced Clinical Research", "city": "Boise", "state": "Idaho", "zip": "83642", "country": "United States", "geoPoint": {"lat": 43.6135, "lon": -116.20345}}, {"facility": "Choose To Lose", "city": "Eagle", "state": "Idaho", "zip": "83616", "country": "United States", "geoPoint": {"lat": 43.69544, "lon": -116.35401}}, {"facility": "Cedar-Crosse Research Center", "city": "Chicago", "state": "Illinois", "zip": "60607", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Alexandria Cardiology Clinic", "city": "Alexandria", "state": "Louisiana", "zip": "71301", "country": "United States", "geoPoint": {"lat": 31.31129, "lon": -92.44514}}, {"facility": "Covington Medical Care", "city": "Mandeville", "state": "Louisiana", "zip": "70471", "country": "United States", "geoPoint": {"lat": 30.35825, "lon": -90.06563}}, {"facility": "Clinical Trials Management, LLC", "city": "Metairie", "state": "Louisiana", "zip": "70006", "country": "United States", "geoPoint": {"lat": 29.98409, "lon": -90.15285}}, {"facility": "MD Medical Research", "city": "Oxon Hill", "state": "Maryland", "zip": "20745", "country": "United States", "geoPoint": {"lat": 38.80345, "lon": -76.9897}}, {"facility": "Bellevue Family Practice", "city": "Bellevue", "state": "Nebraska", "zip": "68005", "country": "United States", "geoPoint": {"lat": 41.13667, "lon": -95.89084}}, {"facility": "Clinical Research Advantage", "city": "Henderson", "state": "Nevada", "zip": "89052", "country": "United States", "geoPoint": {"lat": 36.0397, "lon": -114.98194}}, {"facility": "Albuquerque Clinical Trials, Inc.", "city": "Albuquerque", "state": "New Mexico", "zip": "87102", "country": "United States", "geoPoint": {"lat": 35.08449, "lon": -106.65114}}, {"facility": "University of New Mexico Health Sciences Center", "city": "Albuquerque", "state": "New Mexico", "zip": "87131-0001", "country": "United States", "geoPoint": {"lat": 35.08449, "lon": -106.65114}}, {"facility": "PhysiqueMed Clinical Trials", "city": "Greensboro", "state": "North Carolina", "zip": "27405", "country": "United States", "geoPoint": {"lat": 36.07264, "lon": -79.79198}}, {"facility": "Clinical Trials of America Inc", "city": "Hickory", "state": "North Carolina", "zip": "28601", "country": "United States", "geoPoint": {"lat": 35.73319, "lon": -81.3412}}, {"facility": "University Medical Associates", "city": "Huntersville", "state": "North Carolina", "zip": "28078", "country": "United States", "geoPoint": {"lat": 35.41069, "lon": -80.84285}}, {"facility": "Northstate Clinical Research", "city": "Lenoir", "state": "North Carolina", "zip": "28645", "country": "United States", "geoPoint": {"lat": 35.91402, "lon": -81.53898}}, {"facility": "Carolina Research Center", "city": "Shelby", "state": "North Carolina", "zip": "28150", "country": "United States", "geoPoint": {"lat": 35.29235, "lon": -81.53565}}, {"facility": "Lillestol Research", "city": "Fargo", "state": "North Dakota", "zip": "58103", "country": "United States", "geoPoint": {"lat": 46.87719, "lon": -96.7898}}, {"facility": "Rapid Medical Research, Inc", "city": "Cleveland", "state": "Ohio", "zip": "44122", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Columbus Clinical Research Inc.", "city": "Columbus", "state": "Ohio", "zip": "43213", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Hometown Urgent Care and Research", "city": "Dayton", "state": "Ohio", "zip": "45432", "country": "United States", "geoPoint": {"lat": 39.75895, "lon": -84.19161}}, {"facility": "Blair Medical Associates Inc.", "city": "Altoona", "state": "Pennsylvania", "zip": "16602", "country": "United States", "geoPoint": {"lat": 40.51868, "lon": -78.39474}}, {"facility": "Safe Harbor Clinical Research", "city": "East Providence", "state": "Rhode Island", "zip": "02914", "country": "United States", "geoPoint": {"lat": 41.81371, "lon": -71.37005}}, {"facility": "Pharmacorp Clinical Trials, Inc.", "city": "Charleston", "state": "South Carolina", "zip": "29412", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "DeGarmo Institute of Medical Research", "city": "Greer", "state": "South Carolina", "zip": "29651", "country": "United States", "geoPoint": {"lat": 34.93873, "lon": -82.22706}}, {"facility": "Holston Medical Group, P.C.", "city": "Bristol", "state": "Tennessee", "zip": "37620", "country": "United States", "geoPoint": {"lat": 36.59511, "lon": -82.18874}}, {"facility": "New Phase Research & Development", "city": "Knoxville", "state": "Tennessee", "zip": "37923", "country": "United States", "geoPoint": {"lat": 35.96064, "lon": -83.92074}}, {"city": "Corpus Christi", "state": "Texas", "zip": "78414", "country": "United States", "geoPoint": {"lat": 27.80058, "lon": -97.39638}}, {"facility": "Dallas Diabetes and Endocrine Center", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "West Houston Clinical Research", "city": "Houston", "state": "Texas", "zip": "77055", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Juno Research, LLC", "city": "Houston", "state": "Texas", "zip": "77074", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Texas Center for Drug Development, Inc.", "city": "Houston", "state": "Texas", "zip": "77081", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Juno Research, LLC", "city": "Katy", "state": "Texas", "zip": "77450", "country": "United States", "geoPoint": {"lat": 29.78579, "lon": -95.8244}}, {"facility": "Northeast Clinical Research of San Antonio, LLC", "city": "Schertz", "state": "Texas", "zip": "78154", "country": "United States", "geoPoint": {"lat": 29.55217, "lon": -98.26973}}, {"city": "Sugarland", "state": "Texas", "zip": "77479", "country": "United States", "geoPoint": {"lat": 29.61968, "lon": -95.63495}}, {"facility": "Progressive Clinical Research, LLC", "city": "Bountiful", "state": "Utah", "zip": "84010", "country": "United States", "geoPoint": {"lat": 40.88939, "lon": -111.88077}}, {"facility": "Highland Clinical Research", "city": "Salt Lake City", "state": "Utah", "zip": "84124", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "Burke Internal Medicine, Inc.", "city": "Burke", "state": "Virginia", "zip": "22015", "country": "United States", "geoPoint": {"lat": 38.79345, "lon": -77.27165}}, {"facility": "Manassas Clinical Research Center", "city": "Manassas", "state": "Virginia", "zip": "20110", "country": "United States", "geoPoint": {"lat": 38.75095, "lon": -77.47527}}, {"facility": "The Medical Arts Health Research Group", "city": "Kelowna", "state": "British Columbia", "zip": "V1Y 3G8", "country": "Canada", "geoPoint": {"lat": 49.88307, "lon": -119.48568}}, {"facility": "Diabetes Research Clinic", "city": "Vancouver", "state": "British Columbia", "zip": "V5Z 1L8", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Joanne F. Liutkus Medicine Professional Corporation", "city": "Cambridge", "state": "Ontario", "zip": "N1R7L6", "country": "Canada", "geoPoint": {"lat": 43.3601, "lon": -80.31269}}, {"facility": "Source Unique Research", "city": "Hawkesbury", "state": "Ontario", "zip": "K6A 1A1", "country": "Canada", "geoPoint": {"lat": 45.60009, "lon": -74.61595}}, {"facility": "Nemocnice s poliklinikou Havirov", "city": "Havirov", "state": "Moravskoslezsky kraj", "zip": "736-01", "country": "Czech Republic", "geoPoint": {"lat": 49.77984, "lon": 18.43688}}, {"facility": "Restrial s.r.o.", "city": "Praha 8", "state": "Praha", "zip": "18100", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Synexus Hungary Ltd", "city": "Budapest", "zip": "1036", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Selye J\u00e1nos K\u00f3rh\u00e1z \u00e9s Rendel?int\u00e9zet, Belgy\u00f3gy\u00e1szati Szakrendel\u00e9s", "city": "Kom\u00e1rom", "zip": "2900", "country": "Hungary", "geoPoint": {"lat": 47.74318, "lon": 18.11913}}, {"facility": "Kanizsai Dorottya Hospital", "city": "Nagykanizsa", "zip": "8800", "country": "Hungary", "geoPoint": {"lat": 46.45347, "lon": 16.99104}}, {"facility": "Medifarma 98", "city": "Ny\u00edregyh\u00e1za", "zip": "4400", "country": "Hungary", "geoPoint": {"lat": 47.95539, "lon": 21.71671}}, {"facility": "Borbanya Praxis Kft., Outpatient Clinic", "city": "Ny\u00edregyh\u00e1za", "zip": "4405", "country": "Hungary", "geoPoint": {"lat": 47.95539, "lon": 21.71671}}, {"facility": "Diabetomics India", "city": "Hyderabad", "state": "Andhra Pradesh", "zip": "500034", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"facility": "DHL Research Centre, 2nd Floor", "city": "Ahmadabad", "state": "Gujarat", "zip": "380015", "country": "India"}, {"facility": "Dia Care- A Complete Diabetes Care Center", "city": "Ahmadabad", "state": "Gujarat", "zip": "380015", "country": "India"}, {"facility": "Baroda Medical College and SSG Hospital", "city": "Vadodara", "state": "Gujarat", "zip": "390001", "country": "India", "geoPoint": {"lat": 22.29941, "lon": 73.20812}}, {"facility": "Banker's Heart Institute", "city": "Vadodara", "state": "Gujarat", "zip": "390015", "country": "India", "geoPoint": {"lat": 22.29941, "lon": 73.20812}}, {"facility": "Endocrinology & Diabetes Research Centre", "city": "Bangalore", "state": "Karnataka", "zip": "560003", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Manipal Hospital", "city": "Bangalore", "state": "Karnataka", "zip": "560017", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Endocrinology Diabetes Centre", "city": "Bangalore", "state": "Karnataka", "zip": "560038", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Bangalore Diabetes Hospital", "city": "Bangalore", "state": "Karnataka", "zip": "560043", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "The Bangalore Diabetes Hospital", "city": "Bangalore", "state": "Karnataka", "zip": "560052", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Jnana Sanjeevani Medical Center", "city": "Bangalore", "state": "Karnataka", "zip": "560078", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Vinaya Hospital and Research Centre", "city": "Mangalore", "state": "Karnataka", "zip": "575003", "country": "India", "geoPoint": {"lat": 12.91723, "lon": 74.85603}}, {"facility": "Seth G. S. Medical College and KEM Hospital", "city": "Mumbai", "state": "Maharashtra", "zip": "400012", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"facility": "Institue of Clinical Endocrinology (I.C.E) and Diabetes Care Unit (D.C.U),", "city": "Nagpur", "state": "Maharashtra", "zip": "440010", "country": "India", "geoPoint": {"lat": 21.14631, "lon": 79.08491}}, {"facility": "Getwell Hospital and Research Institute", "city": "Nagpur", "state": "Maharashtra", "zip": "440012", "country": "India", "geoPoint": {"lat": 21.14631, "lon": 79.08491}}, {"facility": "Diabetes Care and Research Centre", "city": "Pune", "state": "Maharashtra", "zip": "411011", "country": "India", "geoPoint": {"lat": 18.51957, "lon": 73.85535}}, {"facility": "KEM Hospital Research Center", "city": "Pune", "state": "Maharashtra", "zip": "411011", "country": "India", "geoPoint": {"lat": 18.51957, "lon": 73.85535}}, {"facility": "Fortis City Centre", "city": "Chandigarh", "state": "Punjab", "zip": "160017", "country": "India", "geoPoint": {"lat": 30.73629, "lon": 76.7884}}, {"facility": "Diabetes and Heart Centre", "city": "Ludhiana", "state": "Punjab", "zip": "141008", "country": "India", "geoPoint": {"lat": 30.91204, "lon": 75.85379}}, {"facility": "Swamy Diabetes Centre", "city": "Chennai", "state": "Tamilnadu", "zip": "600028", "country": "India", "geoPoint": {"lat": 13.08784, "lon": 80.27847}}, {"facility": "Madras Diabetes Research Foundation", "city": "Chennai", "state": "Tamilnadu", "zip": "600086", "country": "India", "geoPoint": {"lat": 13.08784, "lon": 80.27847}}, {"facility": "Kovai Diabetes Speciality Centre & Hospital", "city": "Coimbatore", "state": "Tamilnadu", "zip": "641009", "country": "India", "geoPoint": {"lat": 11.00555, "lon": 76.96612}}, {"facility": "Soroka University Medical Center", "city": "Beer Sheva", "zip": "84101", "country": "Israel", "geoPoint": {"lat": 31.25181, "lon": 34.7913}}, {"facility": "Edith Wolfson Medical Center", "city": "Holon", "zip": "58100", "country": "Israel", "geoPoint": {"lat": 32.01034, "lon": 34.77918}}, {"facility": "Ziv Medical Center Safed-Israel", "city": "Safed", "zip": "13100", "country": "Israel", "geoPoint": {"lat": 32.96465, "lon": 35.496}}, {"facility": "Instituto Jalisciense de Investigaci\u00f3n en Diabetes y Obesidad", "city": "Guadalajara", "state": "Jalisco", "zip": "44600", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Centrum Terapii Wspolczesnej J.M. Jasnorzewska Sp. Komandytowo - Akcyjna", "city": "Lodz", "state": "Lodzkie", "zip": "90242", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "LANDA - Specjalistyczne Gabinety Lekarskie", "city": "Krakow", "state": "Malopolskie", "zip": "30-015", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Niepubliczy Zaklad Opieki Zdrowotnej (NZOZ) Specjalistyczny Osrodek Internistyczno - Diabetologiczny", "city": "Bialystok", "zip": "15-435", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "NZOZ \"Esculap\" S.C.", "city": "Gniewkowo", "zip": "88-140", "country": "Poland", "geoPoint": {"lat": 52.89461, "lon": 18.40785}}, {"facility": "GOU VPO \"Chita State Medical Academy\" of Minzdravsocrazvitie RF", "city": "Chita", "zip": "672090", "country": "Russian Federation", "geoPoint": {"lat": 52.03171, "lon": 113.50087}}, {"facility": "Clinic of New Medical Technology Company Limited", "city": "Dzerzhinskiy", "zip": "140091", "country": "Russian Federation", "geoPoint": {"lat": 55.62945, "lon": 37.85654}}, {"facility": "Kemerovo Regional Clinical Hospital", "city": "Kemerovo", "zip": "650066", "country": "Russian Federation", "geoPoint": {"lat": 55.33333, "lon": 86.08333}}, {"facility": "State Institution of Public Health of Moscow City Endocrinology Dispensary", "city": "Moscow", "zip": "119034", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novosibirsk State Medical University", "city": "Novosibirsk", "zip": "630087", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Reafan, LLC", "city": "Novosibirsk", "zip": "630099", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Rostov State Medical University", "city": "Rostov-on-Don", "zip": "344022", "country": "Russian Federation", "geoPoint": {"lat": 47.23135, "lon": 39.72328}}, {"facility": "Ryazan State Medical University", "city": "Ryazan", "zip": "29005", "country": "Russian Federation", "geoPoint": {"lat": 54.6269, "lon": 39.6916}}, {"facility": "Center \"Diabetes\", LLC", "city": "Samara", "zip": "443067", "country": "Russian Federation", "geoPoint": {"lat": 53.20007, "lon": 50.15}}, {"facility": "Smolensk State Medical Academy, Sanatorium-Preventorium", "city": "Smolensk", "zip": "214019", "country": "Russian Federation", "geoPoint": {"lat": 54.7818, "lon": 32.0401}}, {"facility": "Medinet, LLC", "city": "St. Petersburg", "zip": "190000", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "North-Western State Medical Unversity n.a. I.I.Mechnikov", "city": "St. Petersburg", "zip": "191015", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Saint-Petersburg City Outpatient Clinic#37", "city": "St. Petersburg", "zip": "191119", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Military Medical Academy named after S.M. Kirov", "city": "St. Petersburg", "zip": "191124", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "City Diabetology Center #4, \"City Polyclinic #77\"", "city": "St. Petersburg", "zip": "192012", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Alexanders City Hospital", "city": "St. Petersburg", "zip": "193312", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Clinical Hospital #122 n.a. Sokolov of FMBA", "city": "St. Petersburg", "zip": "194291", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "ANO Medical Centre XXI Century", "city": "St. Petersburg", "zip": "194354", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "City Hospital #38 named after N. A. Semashko", "city": "St. Petersburg", "zip": "196601", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Krestovsky Island Medical Institute, LLC", "city": "St. Petersburg", "zip": "197042", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Federal Centre of Heart, Blood and Endocrinology named after V.A. Almazov", "city": "St. Petersburg", "zip": "197341", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Federal State Budget Military Educational Institution Medical Military Academy n. a. S. M. Kirov", "city": "St. Petersburg", "zip": "198013", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "SPb GBUZ Diagnostic Center #85", "city": "St. Petersburg", "zip": "198255", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "City Hospital named after N.A.Semashko", "city": "Yaroslavl", "zip": "150002", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "Yaroslavl Regional Clinical Hospital", "city": "Yaroslavl", "zip": "150062", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "Centre for Diabetes and Endocrinology Suite 1", "city": "Congella", "state": "Durban", "zip": "4091", "country": "South Africa", "geoPoint": {"lat": -29.87189, "lon": 30.99508}}, {"facility": "Vawda Z Private Practice", "city": "Kwa Zulu Natal", "state": "Durban", "zip": "4091", "country": "South Africa"}, {"facility": "Newkwa Medical Centre", "city": "Newlands West", "state": "Durban", "zip": "4037", "country": "South Africa"}, {"facility": "Drs. Naiker and Naicker Inc.", "city": "Overport", "state": "Durban", "zip": "4001", "country": "South Africa", "geoPoint": {"lat": -29.8348, "lon": 31.00012}}, {"facility": "Synexus Clinical Research SA (Pty) Ltd", "city": "Meyerspark", "state": "Pretoria", "zip": "0102", "country": "South Africa", "geoPoint": {"lat": -25.74111, "lon": 28.32162}}, {"facility": "East Rand Research Trading as Worthwhile Clinical Trials", "city": "Benoni", "zip": "1500", "country": "South Africa", "geoPoint": {"lat": -26.18848, "lon": 28.32078}}, {"facility": "Charlotte Maxeke Johannesburg Academic Hospital", "city": "Johannesburg", "zip": "2193", "country": "South Africa", "geoPoint": {"lat": -26.20227, "lon": 28.04363}}, {"facility": "Aliwal Shoal Medical & Clinical Trial Centre", "city": "Kwa Zulu Natal", "zip": "4170", "country": "South Africa"}, {"facility": "Netcare Umhlanga Medical Centre", "city": "Kwa Zulu Natal", "zip": "4320", "country": "South Africa"}, {"facility": "Helderberg Clinical Trials Centre", "city": "Somerset West", "zip": "7129", "country": "South Africa", "geoPoint": {"lat": -34.08401, "lon": 18.82113}}, {"facility": "Educational Scientific Medical Centre, Donetsk National Medical University", "city": "Donetsk", "zip": "83003", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"facility": "State Institution \"Institute of Problems of Endocrine Pathology n.a. V.Y. Danylevsky of NAMS of Ukra", "city": "Kharkiv", "zip": "61002", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Ukrainian Scientific-and-Practical Center of Endocrine Surgery, Transplantation of Endocrine Organs", "city": "Kyiv", "zip": "02175", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Department of Endocrinology of Railway Clinical Hospital #2 of station \"Kyiv\" of South East Railroad", "city": "Kyiv", "zip": "03049", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Administration of Medical Service and Rehabilitation of \"ARTEM\" State Holding Company", "city": "Kyiv", "zip": "04050", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "National Medical University n.a. O.O. Bogomolets, Chair of Family Medicine based on Outpatient Clini", "city": "Kyiv", "zip": "04050", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "V. P. Komissarenko Institute of Endocrinology and Metabolism of AMS of Ukraine", "city": "Kyiv", "zip": "04114", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Odessa State Medical University", "city": "Odesa", "zip": "65039", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"facility": "Odessa City Policlinic #20", "city": "Odesa", "zip": "65114", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"facility": "Vinnytsya Regional Clinical Endocrinology Dispensary", "city": "Vinnytsya", "zip": "21010", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "580 participants entered the qualifying period; 442 participants were randomized and treated, and comprise the Safety Analysis Set. Of these, 20 participants were excluded due to major eligibility criteria protocol violation or because the participant had no postbaseline data; the remaining 422 participants comprise the Full Analysis Set.", "recruitmentDetails": "Participants were enrolled (during the Qualifying Period) at a total of 112 study sites in Canada, Europe, Asia, Mexico, South Africa, and the United States. The first participant was screened on 28 June 2012. The last participant observation occurred on 01 October 2013.", "groups": [{"id": "FG000", "title": "Placebo+Metformin", "description": "Qualifying period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening) and participants who were \u2265 80% compliant and meeting eligibility criteria continued to the treatment period.\n\nTreatment period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily through Week 24.\n\nParticipants were required to maintain their diet and exercise regimen."}, {"id": "FG001", "title": "Ranolazine+Metformin", "description": "Qualifying period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening) and participants who were \u2265 80% compliant and meeting eligibility criteria continued to the treatment period.\n\nTreatment period: Ranolazine 500 mg (1 x 500 mg tablet) twice daily plus metformin 500 mg/metformin placebo (1 x 500 mg tablet active metformin plus 1 placebo tablet) twice daily on Days 1 through 7, followed by ranolazine 1000 mg (2 x 500 mg tablets) twice daily plus metformin 500 mg/metformin placebo (1 x 500 mg tablet active metformin plus 1 placebo tablet) twice daily from Day 8 through Week 24.\n\nParticipants were required to maintain their diet and exercise regimen."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "222"}, {"groupId": "FG001", "numSubjects": "220"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "182"}, {"groupId": "FG001", "numSubjects": "185"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "40"}, {"groupId": "FG001", "numSubjects": "35"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Hyperglycemia", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Investigator's Discretion", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Subject Non-compliance", "reasons": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Subject Withdrew Consent", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "11"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety Analysis Set: randomized participants who received at least one dose of study treatment.", "groups": [{"id": "BG000", "title": "Placebo+Metformin", "description": "Qualifying period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening) and participants who were \u2265 80% compliant and meeting eligibility criteria continued to the treatment period.\n\nTreatment period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily through Week 24.\n\nParticipants were required to maintain their diet and exercise regimen."}, {"id": "BG001", "title": "Ranolazine+Metformin", "description": "Qualifying period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening) and participants who were \u2265 80% compliant and meeting eligibility criteria continued to the treatment period.\n\nTreatment period: Ranolazine 500 mg (1 x 500 mg tablet) twice daily plus metformin 500 mg/metformin placebo (1 x 500 mg tablet active metformin plus 1 placebo tablet) twice daily on Days 1 through 7, followed by ranolazine 1000 mg (2 x 500 mg tablets) twice daily plus metformin 500 mg/metformin placebo (1 x 500 mg tablet active metformin plus 1 placebo tablet) twice daily from Day 8 through Week 24.\n\nParticipants were required to maintain their diet and exercise regimen."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "222"}, {"groupId": "BG001", "value": "220"}, {"groupId": "BG002", "value": "442"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56", "spread": "8.9"}, {"groupId": "BG001", "value": "56", "spread": "9.3"}, {"groupId": "BG002", "value": "56", "spread": "9.1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "98"}, {"groupId": "BG001", "value": "121"}, {"groupId": "BG002", "value": "219"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "124"}, {"groupId": "BG001", "value": "99"}, {"groupId": "BG002", "value": "223"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "53"}, {"groupId": "BG001", "value": "37"}, {"groupId": "BG002", "value": "90"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "166"}, {"groupId": "BG001", "value": "181"}, {"groupId": "BG002", "value": "347"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "American Indian or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "52"}, {"groupId": "BG001", "value": "54"}, {"groupId": "BG002", "value": "106"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "19"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "160"}, {"groupId": "BG001", "value": "153"}, {"groupId": "BG002", "value": "313"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "82"}, {"groupId": "BG001", "value": "67"}, {"groupId": "BG002", "value": "149"}]}]}, {"title": "Hungary", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "16"}]}]}, {"title": "Czech Republic", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Mexico", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "10"}]}]}, {"title": "Canada", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}]}]}, {"title": "Poland", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}]}]}, {"title": "Ukraine", "categories": [{"measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "64"}]}]}, {"title": "South Africa", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "11"}]}]}, {"title": "Israel", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}, {"title": "Russian Federation", "categories": [{"measurements": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "49"}, {"groupId": "BG002", "value": "86"}]}]}, {"title": "India", "categories": [{"measurements": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "49"}, {"groupId": "BG002", "value": "93"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.2", "spread": "4.46"}, {"groupId": "BG001", "value": "31.6", "spread": "4.95"}, {"groupId": "BG002", "value": "31.4", "spread": "4.71"}]}]}]}, {"title": "Estimated glomerular filtration rate (eGFR)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL/min/1.73m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "90.8", "spread": "20.01"}, {"groupId": "BG001", "value": "89.9", "spread": "21.82"}, {"groupId": "BG002", "value": "90.4", "spread": "20.91"}]}]}]}, {"title": "Glycosylated hemoglobin (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percent HbA1c in blood", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.09", "spread": "0.729"}, {"groupId": "BG001", "value": "8.10", "spread": "0.692"}, {"groupId": "BG002", "value": "8.09", "spread": "0.710"}]}]}]}, {"title": "Fasting Serum Glucose (FSG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "170.0", "spread": "35.97"}, {"groupId": "BG001", "value": "168.8", "spread": "32.86"}, {"groupId": "BG002", "value": "169.4", "spread": "34.42"}]}]}]}, {"title": "Duration of Diabetes", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6.7", "spread": "5.31"}, {"groupId": "BG001", "value": "6.4", "spread": "5.37"}, {"groupId": "BG002", "value": "6.5", "spread": "5.34"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24", "description": "The average (mean) change from baseline in HbA1c at Week 24 was analyzed.", "populationDescription": "Participants in the Full Analysis Set (randomized participants who received \u2265 1 dose of study treatment with a baseline and at least one postbaseline measurement of HbA1c, excluding participants with major eligibility violations, and analyzed based on randomized treatment, regardless of actual treatment received) with available data were analyzed.", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent of HbA1c in blood", "timeFrame": "Baseline; Week 24", "groups": [{"id": "OG000", "title": "Placebo+Metformin", "description": "Qualifying period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening) and participants who were \u2265 80% compliant and meeting eligibility criteria continued to the treatment period.\n\nTreatment period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily through Week 24.\n\nParticipants were required to maintain their diet and exercise regimen."}, {"id": "OG001", "title": "Ranolazine+Metformin", "description": "Qualifying period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening) and participants who were \u2265 80% compliant and meeting eligibility criteria continued to the treatment period.\n\nTreatment period: Ranolazine 500 mg (1 x 500 mg tablet) twice daily plus metformin 500 mg/metformin placebo (1 x 500 mg tablet active metformin plus 1 placebo tablet) twice daily on Days 1 through 7, followed by ranolazine 1000 mg (2 x 500 mg tablets) twice daily plus metformin 500 mg/metformin placebo (1 x 500 mg tablet active metformin plus 1 placebo tablet) twice daily from Day 8 through Week 24.\n\nParticipants were required to maintain their diet and exercise regimen."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "174"}, {"groupId": "OG001", "value": "179"}]}], "classes": [{"title": "HbA1c at Week 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.86", "spread": "1.003"}, {"groupId": "OG001", "value": "7.72", "spread": "1.069"}]}]}, {"title": "Change from baseline in HbA1c at Week 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.20", "spread": "0.949"}, {"groupId": "OG001", "value": "-0.37", "spread": "0.916"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Assuming a common standard deviation of 1.2%, an effective sample size of 400 would provide at least 90% power to detect a statistically significant treatment difference of -0.4% (ranolazine vs. placebo) for the reduction of HbA1c from baseline at Week 24 based on a 2-sided alpha of 0.05 and 1:1 randomization.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.306", "pValueComment": "P-value from a mixed-effect model including terms for baseline HbA1c value, treatment group, visit week, and treatment by visit week interaction. Unstructured covariance matrix was used.", "statisticalMethod": "Mixed Effects Model Analysis", "paramType": "difference in least squares mean (LSM)", "paramValue": "-0.11", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.31", "ciUpperLimit": "0.10", "estimateComment": "The estimation (LSM) is of the placebo-corrected change from baseline."}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Serum Glucose at Week 24", "description": "The average (mean) change from baseline in fasting serum glucose at Week 24 was analyzed.", "populationDescription": "Participants in the Full Analysis Set with available data were analyzed.", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline; Week 24", "groups": [{"id": "OG000", "title": "Placebo+Metformin", "description": "Qualifying period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening) and participants who were \u2265 80% compliant and meeting eligibility criteria continued to the treatment period.\n\nTreatment period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily through Week 24.\n\nParticipants were required to maintain their diet and exercise regimen."}, {"id": "OG001", "title": "Ranolazine+Metformin", "description": "Qualifying period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening) and participants who were \u2265 80% compliant and meeting eligibility criteria continued to the treatment period.\n\nTreatment period: Ranolazine 500 mg (1 x 500 mg tablet) twice daily plus metformin 500 mg/metformin placebo (1 x 500 mg tablet active metformin plus 1 placebo tablet) twice daily on Days 1 through 7, followed by ranolazine 1000 mg (2 x 500 mg tablets) twice daily plus metformin 500 mg/metformin placebo (1 x 500 mg tablet active metformin plus 1 placebo tablet) twice daily from Day 8 through Week 24.\n\nParticipants were required to maintain their diet and exercise regimen."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "171"}, {"groupId": "OG001", "value": "176"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3", "spread": "44.7"}, {"groupId": "OG001", "value": "3", "spread": "42.5"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24", "description": "The average (mean) change from baseline in 2-hour postprandial serum glucose at Week 24 was analyzed.\n\nMixed Meal Tolerance Test (MMTT) Full Analysis Set: randomized participants who received at least one dose of study treatment with a baseline and at least one postbaseline measurement of serum glucose at T=120 minutes during the MMTT, administered under fasting conditions, excluding participants with major eligibility protocol violations; analyzed based on the randomized treatment regardless of actual treatment received.", "populationDescription": "Participants in the MMTT Full Analysis Set with available data were analyzed.", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline; Week 24", "groups": [{"id": "OG000", "title": "Placebo+Metformin", "description": "Qualifying period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening) and participants who were \u2265 80% compliant and meeting eligibility criteria continued to the treatment period.\n\nTreatment period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily through Week 24.\n\nParticipants were required to maintain their diet and exercise regimen."}, {"id": "OG001", "title": "Ranolazine+Metformin", "description": "Qualifying period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening) and participants who were \u2265 80% compliant and meeting eligibility criteria continued to the treatment period.\n\nTreatment period: Ranolazine 500 mg (1 x 500 mg tablet) twice daily plus metformin 500 mg/metformin placebo (1 x 500 mg tablet active metformin plus 1 placebo tablet) twice daily on Days 1 through 7, followed by ranolazine 1000 mg (2 x 500 mg tablets) twice daily plus metformin 500 mg/metformin placebo (1 x 500 mg tablet active metformin plus 1 placebo tablet) twice daily from Day 8 through Week 24.\n\nParticipants were required to maintain their diet and exercise regimen."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "166"}, {"groupId": "OG001", "value": "173"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4", "spread": "54.0"}, {"groupId": "OG001", "value": "7", "spread": "58.2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 24 weeks plus 30 days", "eventGroups": [{"id": "EG000", "title": "Placebo+Metformin", "description": "Qualifying period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening) and participants who were \u2265 80% compliant and meeting eligibility criteria continued to the treatment period.\n\nTreatment period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily through Week 24.\n\nParticipants were required to maintain their diet and exercise regimen.", "seriousNumAffected": 2, "seriousNumAtRisk": 222, "otherNumAffected": 14, "otherNumAtRisk": 222}, {"id": "EG001", "title": "Ranolazine+Metformin", "description": "Qualifying period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening) and participants who were \u2265 80% compliant and meeting eligibility criteria continued to the treatment period.\n\nTreatment period: Ranolazine 500 mg (1 x 500 mg tablet) twice daily plus metformin 500 mg/metformin placebo (1 x 500 mg tablet active metformin plus 1 placebo tablet) twice daily on Days 1 through 7, followed by ranolazine 1000 mg (2 x 500 mg tablets) twice daily plus metformin 500 mg/metformin placebo (1 x 500 mg tablet active metformin plus 1 placebo tablet) twice daily from Day 8 through Week 24.\n\nParticipants were required to maintain their diet and exercise regimen.", "seriousNumAffected": 3, "seriousNumAtRisk": 220, "otherNumAffected": 18, "otherNumAtRisk": 220}], "seriousEvents": [{"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 222}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 220}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 222}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 220}]}, {"term": "Impaired gastric emptying", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 222}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 220}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 222}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 220}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 222}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 220}]}, {"term": "Metabolic acidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 222}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 220}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 222}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 220}]}, {"term": "Lumbar spinal stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 222}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 220}]}], "otherEvents": [{"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 222}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 220}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:\n\n* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or\n* The study has been completed at all study sites for at least 2 years"}, "pointOfContact": {"title": "Clinical Trial Disclosures", "organization": "Gilead Sciences, Inc.", "email": "ClinicalTrialDisclosures@gilead.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000069458", "term": "Ranolazine"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000026941", "term": "Sodium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M4854", "name": "Benzocaine", "relevance": "LOW"}, {"id": "M427", "name": "Ranolazine", "asFound": "Toddlers", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M23177", "name": "Sodium Channel Blockers", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}, {"id": "T433", "name": "Tannic Acid", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "Ot", "name": "Other Dietary Supplements"}]}}, "hasResults": true}